A fiercely competitive three-horse race in spinal muscular atrophy is Evrysdi’s for the taking.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's…